Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice

Transplantation Proceedings

Volumn 37, Issue 4, 2005, Pages 1880-1884

  Naoum, J J ^a   Woodside, K J ^a   Zhang, S ^a   Rychahou, P G ^a   Hunter, G C ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; PROTEIN KINASE B; RAPAMYCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRIACYLGLYCEROL;

ABDOMINAL AORTA; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ATHEROSCLEROTIC PLAQUE; BLOOD ANALYSIS; CELLULAR DISTRIBUTION; CHOLESTEROL DIET; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVATION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KNOCKOUT MOUSE; LIPID ANALYSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCANNING ELECTRON MICROSCOPY; STUDENT T TEST; WESTERN BLOTTING; ZYMOGRAPHY;

ANALYSIS OF VARIANCE; ANIMALS; AORTA; APOLIPOPROTEINS E; ARTERIES; ARTERIOSCLEROSIS; CHOLESTEROL; ENZYME ACTIVATION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; SIROLIMUS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 20344365093     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.02.080     Document Type: Conference Paper

References (26)

1. C. Brattstrom, H. Wilczek, G. Tyden Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin) Transplantation 65 1998 272
2. R.C. Hoogeveen, C.M. Ballantyne, H.J. Pownall Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients Transplantation 72 2001 244
3. M.M. Elloso, N. Azrolan, S.N. Sehgal Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice Am J Transplant 3 2003 62
4. B.S. Oemar, M.R. Tschudi, N. Godoy Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis Circulation 97 1998 494
5. J. Hoffmann, J. Haendeler, A. Aicher Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli important role of nitric oxide Circ Res 89 2001 09
6. P. Libby, M. Aikawa Stabilization of atherosclerotic plaques new mechanisms and clinical targets Nat Med 8 2002 257
7. J.D. Morrisett, G. Abdel-Fattah, B.D. Kahan Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients Transplant Proc 35 Suppl 2003 143S
8. R. Scalia, M.E. Gooszen, S.P. Jones Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice Circulation 103 2001 598
9. U. Laufs, V. La Fata, J. Plutzky Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1998 129
10. K. Kauser, V. da Cunha, R. Fitch Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice Am J Physiol Heart Circ Physiol 278 2000 1679
11. Y. Nakata, N. Maeda Vulnerable atherosclerotic plaque morphology in apolipoprotein E-deficient mice unable to make ascorbic acid Circulation 105 2002 1485
12. Z.S. Galis, G.K. Sukhova, M.W. Lark Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques J Clin Invest 94 1994 493
13. A.C. Li, C.K. Glass The macrophage foam cell as a target for therapeutic intervention Nat Med 8 2002 235
14. S.M. Pham, L.L. Shears, N. Kawaharada High local production of nitric oxide as a possible mechanism by which rapamycin prevents transplant arteriosclerosis Transplant Proc 30 1998 53
15. J.J. Naoum, S. Zhang, K.J. Woodside Aortic eNOS expression and phosphorylation in Apo-E knockout mice differing effects of rapamycin and simvastatin Surgery 136 2004 23
16. A. Brouet, P. Sonveaux, C. Dessy Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins Circ Res 89 2001 66
17. V. Schachinger, A.M. Zeiher Atherogenesis - recent insights into basic mechanisms and their clinical impact Nephrol Dial Transplant 17 2002 055
18. H. Ju, R. Zou, V.J. Venema Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity J Biol Chem 272 1997 8522
19. O. Feron, L. Belhassen, L. Kobzik Endothelial nitric oxide synthase targeting to caveolae Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells J Biol Chem 271 1996 2810
20. O. Feron, C. Dessy, S. Moniotte Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase J Clin Invest 103 1999 97
21. B. Razani, M.P. Lisanti Caveolin-deficient mice insights into caveolar function human disease J Clin Invest 108 2001 553
22. M.E. Davis, D.G. Harrison Cracking down on caveolin role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in modulating endothelial cell nitric oxide production Circulation 103 2001 2
23. E.J. Smart, G.A. Graf, M.A. McNiven Caveolins, liquid-ordered domains, and signal transduction Mol Cell Biol 19 1999 289
24. D. Zhang, M. Bar-Eli, S. Meloche Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals J Biol Chem 279 2004 9683
25. D.M. Lawrence, R.S. Singh, D.P. Franklin Rapamycin suppresses experimental aortic aneurysm growth J Vasc Surg 40 2004 34
26. K. Brew, D. Dinakarpandian, H. Nagase Tissue inhibitors of metalloproteinases evolution, structure and function Biochim Biophys Acta 1477 2000 67